Tolvaptan Teva Training For Healthcare Professionals
Information for healthcare professionals in the UK
Tolvaptan Teva is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. 01
Teva, in conjunction with the Medicines and Healthcare products Regulatory Agency (MHRA), are providing healthcare professionals and patients with an educational programme on Tolvaptan Teva. This programme includes healthcare professional (HCP) training slides and educational materials for HCPs and patients.
Healthcare professionals are required to review the training slides and accompanying educational materials provided on this website and confirm completion of this training by registering their details with Teva. Healthcare professionals will be reminded to refresh this training annually.
Tolvaptan Teva Training Materials
These materials provide important safety information on the risks of Tolvaptan Teva treatment, including liver toxicity, pregnancy prevention, monitoring requirements, dose and method of administration information, as well as the process for reporting adverse events.
This training does not replace the Summary of Product Characteristics (SmPC), which should be read thoroughly before prescribing or dispensing Tolvaptan Teva. Patients should also be advised to read the Patient Information Leaflet (PIL). The SmPC and PIL for Tolvaptan Teva can be found at www.medicines.org.uk/emc.
Healthcare Professional Materials
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search ‘MHRA Yellow Card’ in the Google Play or Apple App Store.
Pregnancy and pregnancy outcomes should also be reported using the same details provided above.
Back to contents.
Tolvaptan Teva - Summary of Product Characteristics available at www.medicines.org.uk/emc